Mur Lura

Notices published in Govt. Gazette No. 19,009 of the 28th December 2012

01/01/2012

COURTS OF JUSTICE DEPARTMENT

Result for the Position of Deputy Registrar at the Courts of Justice Department (Malta)

The Director General, Courts of Justice Department, notifies that the result for the above mentioned position has been published and can be viewed on the notice-board of the Courts of Justice Department (4th Floor), Triq ir-Repubblika, Valletta and that of the Public Service Commission, The Palace, Valletta.

Directorate for Educational Services (DES)

Result of Interviews for Posts of Supply Teachers (Various Subjects) in the Directorate for Educational Services (DES)

The Directorate for Educational Services (DES) notifies that the result of the interviews for the abovementioned posts may be viewed on the notice-board of the Directorate for Educational Services (DSE), Floriana, on the notice-boardof the Public Service Commission, The Palace, Valletta and on the notice-board of the Assistant Director of Education, Victoria, Gozo.

Public Service Commission

Results of the Selection Process for Positions in the Ministry for Home Affairs

It is notified for general information that the results of the selection process for the filling of the under-mentioned positions have been published and may be viewed on the main notice-board situated at the Ministry for Home Affairs, House of Catalunya, Triq Marsamxett, Valletta and on the notice-board of the Office of the Public Service Commission, The Palace, Valletta.

The positions are the following:

Liaison Officer (Victim Support Unit)

Parole Clerk

Accounting Officer

Psychologist

MINISTRY OF FINANCE, THE ECONOMY AND INVESTMENT

Result of Interview for the Position of Senior Manager (IT) in the Customs Department in the Ministry of Finance, the Economy and Investment

The Permanent Secretary in the Ministry of Finance, the Economy and Investment notifies that the result of the interview for the above mentioned position may be viewed on the main notice-board at the Customs Department, Lascaris, Valletta and on the notice-board of the Office of the Public Service Commission, The Palace, Valletta

Directorate for Educational Services

Notification on the Validity Period of Results for the Calls Mentioned Hereunder

Supply Kindergarten Assistant

With reference to the call for applications for Supply Kindergarten Assistant published on the 3rd December 2010 in Government Gazette No. 18,682 and its subsequent extension, it is notified that all result lists (order of merit lists) published in terms of this call have a validity period of one year from the date of publication of result list or until they are exhausted, which ever comes first.

Supply Learning Support Assistant

With reference to the call for applications for Supply Learning Support Assistant published on the 9th November 2010 in Government Gazette No. 18,669 and its subsequent extension, it is notified that all result lists (order of merit lists) published in terms of this call have a validity period of one year from the date of publication of result list or until they are exhausted, which ever comes first.

Supply Teacher

With reference to the call for applications for Supply Teacher published on 20th May 2011 in Government Gazette No. 18,752 and its subsequent extension, it is notified that all result lists (order of merit lists) published in terms of this call have a validity period for one (1) year from date of publication of the result list or until the result list is exhausted, whichever comes first.

MINISTRY OF EDUCATION AND EMPLOYMENT

Post of Social Worker in the Directorate for Educational Services (DES)

Correction

With reference to the call for applications for the above mentioned post published in Government Gazette No. 19,001 of the 11thDecember 2012, it is notified that part ofparagraph 2.3, should read as follows:

“…the selected candidate has not been appointed in terms of paragraph 4.1 (iv)…” and not paragraph 6.1 as written.

It is to be noted that paragraph 4.3 should read as follows:

4.3 Selected candidates who are appointed in terms of 4.1 (v) above will enter in Salary Scale 12 which in 2012 is €14,282 per annum rising by annual increments of €354 up to a maximum of €16,406 and will progress to Salary Scale 10 (currently €16,197.98 per annum rising by annual increment of €407.67 up to a maximum of €18,644 on completion of five (5) years of service in the grade subject to satisfactory performance.

SUPERINTENDENCE OF CULTURAL HERITAGE

National Inventory of the Cultural Property of the Maltese Islands

THE following inventory of sites and objects is being published hereunder, in terms of Article 7 (5) (a) of the Cultural Heritage Act (Cap. 445).

More detailed Inventory data forms may be obtained from:

http://www.culturalheritage.gov.mt/page.asp?p=21409&l=1

National Inventory of the Cultural Property of the Maltese Islands

NICMPI. Inv. No.NameLocality

01125	Auberge D’Aragon	Valletta
01126	Municipal Palace - Banca Guratale	Valletta
01127	Auberge de Castille et Leon	Valletta
01128	Auberge de Baviere	Valletta
01129	Auberge D’Italie	Valletta
01130	St.John’s Co-Cathedral	Valletta
01131	Palazzo Parisio	Valletta
01132	Castellania	Valletta
01133	Museum of Fine Arts	Valletta
01134	Grandmaster Palace	Valletta
01135	Auberge de Provence	Valletta
01136	Palazzo De La Salle	Valletta
01137	Sacra Infermeria	Valletta
01138	Barriera Stores	Valletta
01139	Old University	Valletta
01140	Manoel Theatre	Valletta
01141	Bibliotheca	Valletta
01142	Cancelleria	Valletta
01143	Triton Fountain	Valletta
01144	Great Siege Monument	Valletta
01145	Palazzo Caraffa	Valletta
01146	The Mall (Maglio Gardens)	Floriana
01147	Argotti Gardens	Floriana
01148	Villino Bonnici	Floriana
01149	Pinto Stores	Floriana
01150	Villa Bologna	Attard
01151	Rose Ville	Attard
01152	San Antonio Palace and Gardens	Attard
01153	Wignacourt Aqueduct	Attard
01154	Palazzo Bosio	Balzan
01155	Wignacourt Aqueduct	Balzan
01156	Villa Macedonia and Gardens	Balzan
01157	Inquisitor’s Palace	Birgu
01158	Auberge de France	Birgu
01159	Auberge d’ Allemagne	Birgu
01160	Auberge d’ Angleterre	Birgu
01161	Auberge d’ Aragon	Birgu
01162	Auberge d’ Auvergne et Provence	Birgu
01163	Auberge de Castille et Portugal (Leon)	Birgu
01164	Auberge d’Italie	Birgu
01165	Akwadott ta’ Wignacourt/Wignacourt Aqueduct	Birkirkara
01166	Palm Lodge, Pegasus and Kalimera	Birżebbuġa
01167	Il-Ġnien tal-Kmand	Gudja
01168	Palazzo Dorell	Gudja
01169	Lazzaretto	Gżira
01170	Palazzo Vecchio	Gżira
01171	Villa Gzira	Gżira
01172	The Cottage	Kalkara
01173	Villa Portelli	Kalkara
01174	Kalkara Naval Cemetery	Kalkara
01175	Red House	Kalkara
01176	Palazzo Francia	Lija
01177	Villa Gourgion	Lija
01178	Villa Violette	Marsa
01179	Villa Apap Bologna	Marsakala
01180	Villa Glenberg	Marsakala
01181	Villa Agius Catania	Marsaxlokk
01182	Corner Premises	Marsaxlokk
01183	Casa Herbert	Marsaxlokk
01184	Palazz Vilhena/Palazzo Vilhena	Mdina
01185	Corte Capitanale	Mdina
01186	Maltacom Building	Mdina
01187	Palazzo Testaferrata	Mdina
01188	Il-Banka Guratale/Banca Giuratale	Mdina
01189	Dar tal-Maġistrat/Casa Del Magistrato	Mdina
01190	Palazzo Santa Sofia	Mdina
01191	Palazzo Costanzo	Mdina
01192	Casa Mdina	Mdina
01193	Palazz Falzon u Ġonna/Palazzo Falzon and Garden	Mdina
01194	Palazz Ferriol/Palazzo Ferriol	Mdina
01195	Villa Marija	Rabat (Malta)
01196	Herald’s Loggia	Mdina
01197	Għajn Ħammam Wash House	Rabat (Malta)
01198	Xara Palace Hotel	Mdina
01199	Howard Gardens	Mdina
01200	Villa Luigisland	Rabat (Malta)
01201	Devil’s Farmhouse	Mellieħa
01202	The Old Hospital	Mqabba
01203	Imtarfa Military Hospital and Garden	Mtarfa
01204	Isolation Hospital	Mtarfa
01205	Palazzo Parisio	Naxxar
01206	Villa Frere and Garden	Pietà
01207	St. Lukes Hospital	Pietà
01208	Palazzo Stagna	Ħal Qormi
01209	Il-Ġnien tal-Kmand	Safi
01210	Villa Leoni	San Ġiljan
01211	Villa Priuli	San Ġiljan
01212	Balluta Buildings	San Ġiljan
01213	Villa Blanche	San Ġiljan
01214	Villa Cassar Torregiani	San Ġiljan
01215	Villa Fieres	San Ġiljan
01216	Villa Rosa	San Ġiljan
01217	San Giuliano Restaurant	San Ġiljan
01218	Dragonara Palace	San Ġiljan
01219	La Maltija Restaurant	San Ġiljan
01220	The Stables	San Ġiljan
01221	St. Julian’s Band Club	San Ġiljan
01222	/Ta’ Xindi Farmhouse	San Gwann
01223	Villa Preziosi	San Pawl il-Baħar
01224	Villino Chappelle	San Pawl il-Baħar
01225	Palazzo Pescatore and Gardens	San Pawl il-Baħar
01226	Palazzo Manuel	Santa Venera
01227	Conservatorio Vincenzo Bugeja	Santa Venera
01228	Istituto Technico Vincenzo Bugeja	Santa Venera
01229	/Wignacourt Aqueduct	Santa Venera
01230	Il-Ġnien Tal-Kmand	Siġġiewi
01231	Inquisitors Palace and Gardens	Siġġiewi
01232	Old Fortified House	Siġġiewi
01233	Villa Louise	Sliema
01234	Villa Drago	Sliema
01235	/Government School	Sliema
01236	Majestic Theatre	Sliema
01237	Bishop’s Palace	Rabat (Għawdex)
01238	Cagliares Palace	Rabat (Għawdex)
01239	Qorti/Law Courts	Rabat (Għawdex)
01240	Natural Science Museum	Rabat (Għawdex)
01241	Maħżen/Magazines (Craft Shop)	Rabat (Għawdex)
01242	Mużew tal-Katidral/Cathedral Museum	Rabat (Għawdex)
01243	The Old Gatehouse	Rabat (Għawdex)
01244	Mużew tal-Arkeoloġija/Archaeology Museum	Rabat (Għawdex)
01245	Villa Buleben	Żebbuġ
01246	Il-Ġnien tal-Kmand	Żebbuġ
01247	Villa Cagliares	Żejtun
01248	Cemetery of St. Roque	Żejtun
01249	Il-Ġnien tal-Kmand	Żejtun

National Anti-Doping ORGANISATION

With reference to Articles 5.1 and 5.2 of Legal Notice No. 281 of 2011, the National Anti-Doping Organisation notifies that the List of Prohibited Substances and Methods 2013 shown hereunder will come into force on the 1st January, 2013.

THE 2013 PROHIBITED LIST

WORLD ANTI-DOPING CODE

Valid 1 January 2013

In accordance with Article 4.2.2 of the World Anti-Doping Code, all Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2, S4.4, S4.5, S6.a, and Prohibited Methods M1, M2 and M3.

SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES

(IN- AND OUT-OF-COMPETITION)

PROHIBITED SUBSTANCES

S0. NON-APPROVED SUBSTANCES

Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.

S1. ANABOLIC AGENTS

Anabolic agents are prohibited.

1. Anabolic Androgenic Steroids (AAS)

a. Exogenous* AAS, including:

1-androstenediol (5α-androst-1-ene-3β,17β-diol ); 1-androstenedione (5α-androst-1-ene-3,17-dione); bolandiol (estr-4-ene-3β,17β-diol ); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol ([1,2]oxazolo[4’,5’:2,3]pregna-4-en-20-yn-17α-ol); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol); drostanolone; ethylestrenol (19-norpregna-4-en-17α-ol); fluoxymesterone; formebolone; furazabol (17α-methyl[1,2,5]oxadiazolo[3’,4’:2,3]-5α-androstan-17β-ol); gestrinone; 4-hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); methandriol; methasterone (17β-hydroxy-2α,17α-dimethyl-5α-androstan-3-one); methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one); methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one); methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one); methyltestosterone; metribolone (methyltrienolone, 17β-hydroxy-17α-methylestra-4,9,11-trien-3-one); mibolerone; nandrolone; 19-norandrostenedione (estr-4-ene-3,17-dione); norboletone; norclostebol; norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone; prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1’H-pyrazolo[3,4:2,3]-5α-androstane); quinbolone; stanozolol; stenbolone; 1-testosterone (17β-hydroxy-5α-androst-1-en-3-one); tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α-pregna-4,9,11-trien-3-one); trenbolone (17β-hydroxyestr-4,9,11-trien-3-one); and other substances with a similar chemical structure or similar biological effect(s).

b. Endogenous** AAS when administered exogenously:

androstenediol (androst-5-ene-3β,17β-diol); androstenedione (androst-4-ene-3,17-dione); dihydrotestosterone (17β-hydroxy-5α-androstan-3-one); prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one); testosterone;

and their metabolites and isomers, including but not limited to:

5α-androstane-3α,17α-diol; 5α-androstane-3α,17β-diol; 5α-androstane-3β,17α-diol; 5α-androstane-3β,17β-diol; androst-4-ene-3α,17α-diol; androst-4-ene-3α,17β-diol; androst-4-ene-3β,17α-diol; androst-5-ene-3α,17α-diol; androst-5-ene-3α,17β-diol; androst-5-ene-3β,17α-diol; 4-androstenediol (androst-4-ene-3β,17β-diol); 5-androstenedione (androst-5-ene-3,17-dione); epi-dihydrotestosterone; epitestosterone; etiocholanolone; 3α-hydroxy-5α-androstan-17-one; 3β-hydroxy-5α-androstan-17-one; 7α-hydroxy-DHEA ; 7β-hydroxy-DHEA ; 7-keto-DHEA; 19-norandrosterone; 19-noretiocholanolone.

2. Other Anabolic Agents, including but not limited to:

Clenbuterol, selective androgen receptor modulators (SARMs), tibolone, zeranol, zilpaterol.

For purposes of this section:

* “exogenous” refers to a substance which is not ordinarily capable of being produced by the body naturally.

** “endogenous” refers to a substance which is capable of being produced by the body naturally.

S2. PEPTIDE HORMONES, GROWTH FACTORS AND RELATED SUBSTANCES

The following substances and their releasing factors are prohibited:

1. Erythropoiesis-Stimulating Agents [e.g. erythropoietin (EPO), darbepoetin (dEPO), hypoxia-inducible factor (HIF) stabilizers, methoxy polyethylene glycol-epoetin beta (CERA), peginesatide (Hematide)];

2. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) in males;

3. Corticotrophins;

4. Growth Hormone (GH), Insulin-like Growth Factor-1 (IGF-1), Fibroblast Growth Factors (FGFs), Hepatocyte Growth Factor (HGF), Mechano Growth Factors (MGFs), Platelet-Derived Growth Factor (PDGF), Vascular-Endothelial Growth Factor (VEGF) as well as any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching;

and other substances with similar chemical structure or similar biological effect(s).

S3. BETA-2 AGONISTS

All beta-2 agonists, including all optical isomers (e.g. d- and l-) where relevant, are prohibited except inhaled salbutamol (maximum 1600 micrograms over 24 hours), inhaled formoterol (maximum delivered dose 54 micrograms over 24 hours) and salmeterol when taken by inhalation in accordance with the manufacturers’ recommended therapeutic regimen.

The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic inhaled dose up to the maximum indicated above.

S4. HORMONE AND METABOLIC MODULATORS

The following are prohibited:

1. Aromatase inhibitors including, but not limited to: aminoglutethimide, anastrozole, androsta-1,4,6-triene-3,17-dione (androstatrienedione), 4-androstene-3,6,17 trione (6-oxo), exemestane, formestane, letrozole, testolactone.

2. Selective estrogen receptor modulators (SERMs) including, but not limited to: raloxifene, tamoxifen, toremifene.

3. Other anti-estrogenic substances including, but not limited to: clomiphene, cyclofenil, fulvestrant.

4. Agents modifying myostatin function(s) including, but not limited, to: myostatin inhibitors.

5. Metabolic modulators:

a) Insulins

b) Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists (e.g. GW 1516), PPARδ-AMP-activated protein kinase (AMPK) axis agonists (e.g. AICAR)

S5. DIURETICS AND OTHER MASKING AGENTS

Masking agents are prohibited. They include:

Diuretics, desmopressin, plasma expanders (e.g. glycerol; intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol), probenecid; and other substances with similar biological effect(s).

Local administration of felypressin in dental anaesthesia is not prohibited.

Diuretics include:

Acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamterene; and other substances with a similar chemical structure or similar biological effect(s) (except drospirenone, pamabrom and topical dorzolamide and brinzolamide, which are not prohibited).

The use In- and Out-of-Competition, as applicable, of any quantity of a substance subject to threshold limits (i.e. formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine) in conjunction with a diuretic or other masking agent requires the deliverance of a specific Therapeutic Use Exemption for that substance in addition to the one granted for the diuretic or other masking agent.

PROHIBITED METHODS

M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS

The following are prohibited:

1. The administration or reintroduction of any quantity of autologous, homologous or heterologous blood or red blood cell products of any origin into the circulatory system.

2. Artificially enhancing the uptake, transport or delivery of oxygen, including, but not limited to, perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products), excluding supplemental oxygen.

3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.

M2. CHEMICAL AND PHYSICAL MANIPULATION

The following are prohibited:

1. Tampering, or attempting to tamper, in order to alter the integrity and validity of Samples collected during Doping Control. These include but are not limited to urine substitution and/or adulteration (e.g. proteases).

2. Intravenous infusions and/or injections of more than 50 mL per 6 hour period except for those legitimately received in the course of hospital admissions or clinical investigations.

M3. GENE DOPING

The following, with the potential to enhance sport performance, are prohibited:

1. The transfer of polymers of nucleic acids or nucleic acid analogues;

2. The use of normal or genetically modified cells.

SUBSTANCES AND METHODS

PROHIBITED IN-COMPETITION

In addition to the categories S0 to S5 and M1 to M3 defined above, the following categories are prohibited

In-Competition:

PROHIBITED SUBSTANCES

S6. STIMULANTS

All stimulants, including all optical isomers (e.g. d- and l-) where relevant, are prohibited, except imidazole derivatives for topical use and those stimulants included in the 2013 Monitoring Program*.

Stimulants include:

a: Non-Specified Stimulants:

Adrafinil; amfepramone; amiphenazole; amphetamine; amphetaminil; benfluorex; benzphetamine; benzylpiperazine; bromantan; clobenzorex; cocaine; cropropamide; crotetamide; dimethylamphetamine; etilamphetamine; famprofazone; fencamine; fenetylline; fenfluramine; fenproporex; furfenorex; mefenorex; mephentermine; mesocarb; methamphetamine(d-); p-methylamphetamine; methylenedioxyamphetamine; methylenedioxymethamphetamine; modafinil; norfenfluramine; phendimetrazine; phenmetrazine; phentermine; 4-phenylpiracetam (carphedon); prenylamine; prolintane.

A stimulant not expressly listed in this section is a Specified Substance.

b: Specified Stimulants (examples):

Adrenaline**; cathine***; ephedrine****; etamivan; etilefrine; fenbutrazate; fencamfamin; heptaminol; isometheptene; levmetamfetamine; meclofenoxate; methylephedrine****; methylhexaneamine (dimethylpentylamine); methylphenidate; nikethamide; norfenefrine; octopamine; oxilofrine (methylsynephrine); parahydroxyamphetamine; pemoline; pentetrazol; phenpromethamine; propylhexedrine; pseudoephedrine*****; selegiline; sibutramine; strychnine; tuaminoheptane; and other substances with a similar chemical structure or similar biological effect(s).

* The following substances included in the 2013 Monitoring Program (bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradol, synephrine) are not considered as Prohibited Substances.

** Local administration (e.g. nasal, ophthalmologic) of Adrenaline or co-administration with local anaesthetic agents is not prohibited.

*** Cathine is prohibited when its concentration in urine is greater than 5 micrograms per milliliter.

**** Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 micrograms per milliliter.

***** Pseudoephedrine is prohibited when its concentration in urine is greater than 150 micrograms per milliliter.

S7. NARCOTICS

The following are prohibited:

Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocine, pethidine.

S8. CANNABINOIDS

Natural (e.g. cannabis, hashish, marijuana) or synthetic delta 9-tetrahydrocannabinol (THC) and cannabimimetics (e.g. “Spice”, JWH018, JWH073, HU-210) are prohibited.

S9. GLUCOCORTICOSTEROIDS

All glucocorticosteroids are prohibited when administered by oral, intravenous, intramuscular or rectal routes.

SUBSTANCES PROHIBITED IN PARTICULAR SPORTS

P1. ALCOHOL

Alcohol (ethanol) is prohibited In-Competition only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold (haematological values) is 0.10 g/L.

• Aeronautic (FAI)

• Archery (FITA)

• Automobile (FIA)

• Karate (WKF)

• Motorcycling (FIM)

• Powerboating (UIM)

P2. BETA-BLOCKERS

Unless otherwise specified, beta-blockers are prohibited In-Competition only, in the following sports.

• Archery (FITA) (also prohibited Out-of-Competition)

• Automobile (FIA)

• Billiards (all disciplines) (WCBS)

• Darts (WDF)

• Golf (IGF)

• Shooting (ISSF, IPC) (also prohibited Out-of-Competition)

• Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air

Beta-blockers include, but are not limited to, the following:

Acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol.

MARSA LOCAL COUNCIL

Removal of Motor Vehicles and Encumbering Objects

The Marsa Local Council would like to inform the general public that all derelict motor vehicles and other encumbering objects have to be removed from all streets in Marsa by not later than Monday 14th January 2013.After the mentioned date the Council would have no other alternativethan to proceed as per Legal Subsidiary Notice LS65.13 regulationsregarding clamping and removal of motor vehicles and encumbering objects.